Scholars Central

Conference abstractPublished 20 Aug 2018

Biosimilars: A biologic revolution - Implications for safety

Authors: Asif Mahmood

Pfizer, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

A fundamental regulatory requirement of biosimilarity is that there are no clinically meaningful differences between the biologic product (i.e. biosimilar) and the reference product in terms of quality, safety, and efficacy. Patient safety is a key consideration throughout the step-wise development of a biosimilar that continues through post-marketing safety monitoring. Because biologic products, including monoclonal antibodies, by their very nature are capable of eliciting immune responses in humans; immunogenicity is a focus of safety assessments during development. An immune response may lead to altered efficacy or compromised safety. Specific effects of immune responses include an immune response that may include immune complex formation resulting in decreased or increased clearance of the biologic and neutralization of the activity of the biologic. Changes in manufacturing, purification, or packaging, as well as shipping and storage conditions, have also the potential to impact the molecular structure of the biologic product and, hence, its immunogenic potential. Additionally immunogenicity also can be impacted by the dose, formulation, and route of administration, as well as individual patient factors such as atopy and immunosuppression. Manufacturing & Safety: Because even small alterations in the source materials or production process of any biologic product may lead to changes in molecular structure, and potentially its biologic effects, manufacturing processes should be carefully controlled at each step. During development of the biosimilar, it is critical that not only the primary amino acid sequences but also higher-order structures be reproduced to the greatest extent possible. This is an important consideration for the biosimilar manufacturer given the proprietary (and usually confidential) nature of the original manufacturing process of the reference product, as well as subsequent changes. Nevertheless, even manufacturers of reference products may encounter significant batch-to-batch variations. Safety also can be compromised by process-related impurities from cell substrates (e.g., host cell DNA and host cell proteins), cell culture components (e.g., antibiotics and media components), and downstream processing steps (e.g., reagents, residual solvents, endotoxins, and bioburden). Formulation, Packaging & Safety: Formulation differences of the biosimilar relative to the reference product are permitted provided the manufacturer of the biosimilar submits evidence demonstrating the differences are not clinically meaningful. Clinically meaningful differences could include a difference in the expected range of safety, purity, and potency between the biosimilar and reference product, whereas slight differences in rates of occurrence of adverse events would not be considered clinically meaningful, and even could occur between studies of the same reference product.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Asif Mahmood”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels